Login to Your Account



Phase IIb Data Early but Promising

Possible Accelerated Approval Path 'EMERGE[s]' for CDX-011

By Jennifer Boggs
Managing Editor

Friday, May 25, 2012
Celldex Therapeutics Inc. is eyeing an accelerated approval pathway after preliminary Phase IIb data showed impressive response rates in three subsets of heavily pretreated breast cancer patients given glycoprotein NMB (GPNMB)-targeting antibody-drug conjugate CDX-011 (glembatumumab vedotin).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription